Jane Street
CLDX icon

Jane Street’s Celldex Therapeutics CLDX Stock Holding History

Jane Street’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Buy
+20,300
New +$553K ﹤0.01% 7451
2025
Q1 		– Sell
-101,800
Closed -$2.57M – 9551
2024
Q4 		$2.57M Sell
101,800
-34,000
-25% -$924K ﹤0.01% 3688
2024
Q3 		$4.62M Buy
+135,800
New +$5.17M ﹤0.01% 2992
2024
Q2 		– Sell
-54,900
Closed -$2.3M – 9449
2024
Q1 		$2.3M Buy
54,900
+44,000
+404% +$1.81M ﹤0.01% 3874
2023
Q4 		$432K Buy
+10,900
New +$321K ﹤0.01% 7009
2023
Q2 		– Sell
-33,000
Closed -$1.19M – 8755
2023
Q1 		$1.19M Buy
33,000
+18,200
+123% +$785K ﹤0.01% 4700
2022
Q4 		$660K Sell
14,800
-1,900
-11% -$67.8K ﹤0.01% 5668
2022
Q3 		$469K Sell
16,700
-462,700
-97% -$14.2M ﹤0.01% 6803
2022
Q2 		$12.9M Buy
479,400
+404,600
+541% +$11.7M 0.01% 1471
2022
Q1 		$2.55M Sell
74,800
-2,800
-4% -$89.5K ﹤0.01% 4278
2021
Q4 		$3M Buy
77,600
+23,500
+43% +$1.02M ﹤0.01% 3686
2021
Q3 		$2.92M Buy
54,100
+37,600
+228% +$1.76M ﹤0.01% 3716
2021
Q2 		$552K Sell
16,500
-5,400
-25% -$148K ﹤0.01% 7048
2021
Q1 		$451K Sell
21,900
-26,200
-54% -$602K ﹤0.01% 6993
2020
Q4 		$843K Buy
48,100
+4,000
+9% +$72K ﹤0.01% 4942
2020
Q3 		$654K Buy
44,100
+11,200
+34% +$131K ﹤0.01% 4756
2020
Q2 		$428K Buy
+32,900
New +$146K ﹤0.01% 5312
2016
Q1 		– Sell
-1,827
Closed -$430K – 4096
2015
Q4 		$430K Buy
+1,827
New +$398K ﹤0.01% 2671
2015
Q2 		– Sell
-540
Closed -$226K – 3653
2015
Q1 		$226K Sell
540
-267
-33% -$95.5K ﹤0.01% 2770
2014
Q4 		$221K Buy
+807
New +$201K ﹤0.01% 2131

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Jane Street's CLDX Position: Q1 2026 in Review

Jane Street opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 90,321 shares worth $2.86M. The stake represents ﹤0.01% of the portfolio and ranks #4431 among its holdings. This is a return to the name: Jane Street previously reported a position in CLDX as recently as Q2 2025.

Jane Street first reported a position in CLDX in Q2 2013 and has held it in 32 quarters since. The position peaked at $7.42M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Jane Street held 90,321 shares of Celldex Therapeutics worth $2.86M as of Q1 2026.
  • Celldex Therapeutics was a new Jane Street position in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4431 holding.
  • Jane Street first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 32 quarters since.
  • Jane Street's Celldex Therapeutics position peaked at $7.42M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.